Blake Borgeson - 03 Jan 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
03 Jan 2022
Net transactions value
-$173,528
Form type
4
Filing time
05 Jan 2022, 19:39:46 UTC
Previous filing
23 Dec 2021
Next filing
05 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +555 +0.01% $0.000000 7,660,771 03 Jan 2022 Direct F1
transaction RXRX Class A Common Stock Sale $173,528 -9,625 -0.13% $18.03 7,651,146 04 Jan 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
F2 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.00 to $18.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.